Ispire Technology Inc. ("Ispire" or the "Company") ((ISPR), a trailblazer in vaping technology and precision dosing, announced that it has entered into a joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) ("Jincheng Pharma"), a global pharmaceutical company, to manufacture and commercialize nicotine pouch products.
The joint venture marks Ispire's entry into the rapidly expanding oral nicotine category, broadening its portfolio beyond vaping hardware and positioning the Company in one of the fastest-growing segments of the global nicotine market. According to Grand View Research, the nicotine pouch market was approximately $7 billion in 2025 and is projected to grow at nearly 25% annually through 2033, potentially exceeding $40 billion.
Login to comment